Wall Street analysts expect Endo International plc (NASDAQ:ENDP) (TSE:ENL) to post $680.67 million in sales for the current quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Endo International’s earnings, with the highest sales estimate coming in at $696.00 million and the lowest estimate coming in at $671.52 million. Endo International posted sales of $875.73 million in the same quarter last year, which suggests a negative year over year growth rate of 22.3%. The firm is scheduled to issue its next earnings report on Tuesday, August 14th.
According to Zacks, analysts expect that Endo International will report full-year sales of $2.75 billion for the current financial year, with estimates ranging from $2.71 billion to $2.78 billion. For the next year, analysts anticipate that the company will post sales of $2.76 billion per share, with estimates ranging from $2.65 billion to $2.93 billion. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover Endo International.
Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its earnings results on Tuesday, May 8th. The company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.12. The business had revenue of $700.53 million during the quarter, compared to analysts’ expectations of $691.94 million. Endo International had a negative net margin of 75.58% and a positive return on equity of 143.46%. The business’s revenue for the quarter was down 32.5% compared to the same quarter last year. During the same period in the previous year, the company earned $1.23 earnings per share.
Endo International stock traded up $0.23 during trading hours on Friday, hitting $6.18. The stock had a trading volume of 150,538 shares, compared to its average volume of 5,113,884. The company has a debt-to-equity ratio of -1,161.84, a quick ratio of 0.88 and a current ratio of 1.06. The stock has a market capitalization of $1.34 billion, a PE ratio of 1.61 and a beta of 0.34. Endo International has a 12-month low of $5.27 and a 12-month high of $14.15.
A number of hedge funds have recently made changes to their positions in the business. Paloma Partners Management Co bought a new position in shares of Endo International in the fourth quarter worth approximately $122,000. Oakbrook Investments LLC bought a new position in shares of Endo International in the fourth quarter worth approximately $133,000. Xact Kapitalforvaltning AB bought a new position in shares of Endo International in the fourth quarter worth approximately $157,000. Elkfork Partners LLC bought a new position in shares of Endo International in the fourth quarter worth approximately $194,000. Finally, Neuburgh Advisers LLC boosted its position in shares of Endo International by 84.2% in the first quarter. Neuburgh Advisers LLC now owns 36,234 shares of the company’s stock worth $215,000 after purchasing an additional 16,566 shares during the period. 98.38% of the stock is owned by institutional investors and hedge funds.
Endo International Company Profile
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.